Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia - prospective open cohort analyses of the ALLR3 trial
- Masurekar, A.
- Parker, C.
- Shanyinde, M.
- Moorman, A.
- Hancock, J.
- Sutton, R.
- Ancliff, P.
- Morgan, M.
- Goulden, N.
- Fraser, C.
- Hoogerbrugge, P.
- Revesz, T.
- Darbyshire, P.
- Krishnan, S.
- Love, S.
- Saha, V.
DOIAbstract
The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age <10 years, progenitor-B cell disease, good-risk cytogenetics and those receiving Mitoxantrone. ...
Add to ORKG